“`html
Cadrenal Therapeutics, Inc. (CVKD) announced on September 15, 2025, the acquisition of a portfolio of Factor XIa inhibitors from eXIthera Pharmaceuticals, which includes frunexian, a Phase 2-ready IV Factor XIa inhibitor aimed at preventing coagulation during acute care settings like cardiopulmonary bypass.
Additionally, Cadrenal is prioritizing a clinical trial for tecarfarin in early 2026, targeting patients with End-Stage Kidney Disease transitioning to dialysis, a population with high cardiovascular event risks and a clear need for effective anticoagulant therapies.
Cadrenal’s DCF model values the company at $30.00 per share, while their second-quarter 2025 financial report indicated no revenues and a cash position of approximately $5.6 million, sufficient to sustain operations for the next 12 months. However, the company will need to raise additional capital for ongoing clinical trials.
“`
